Dr. Christopher M. Wilson, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 512
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Indiana University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
IN license 01057419
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
- Hendricks Regional Health Danville, IN
- Franciscan Health Mooresville Mooresville, IN
- Putnam County Hospital Greencastle, IN
Medical groups
- American Health Network of Indiana LLC (208 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 512
- Services billed
- 1,348
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 370 | 292 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 117 | 68 |
| Insertion of needle into vein for collection of blood sample | 93 | 76 |
| Established patient office or other outpatient visit, 40-54 minutes | 80 | 61 |
| New patient office or other outpatient visit, 45-59 minutes | 80 | 80 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 41 | 41 |
| Nerve conduction, 7-8 studies | 33 | 33 |
| Established patient office or other outpatient visit, 20-29 minutes | 32 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
| Nerve conduction, 9-10 studies | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Avon, IN | 326 |
| Memantine Hcl Other prescribers in Avon, IN | 250 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Avon, IN | 234 |
| Gabapentin Other prescribers in Avon, IN | 216 |
| Topiramate Other prescribers in Avon, IN | 210 |
| Pregabalin Other prescribers in Avon, IN | 175 |
| Levetiracetam Other prescribers in Avon, IN | 172 |
| Clonazepam Other prescribers in Avon, IN | 133 |
| Duloxetine Hcl Other prescribers in Avon, IN | 120 |
| Zonisamide Other prescribers in Avon, IN | 116 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 32 payments worth $14,624 in total to this clinician.
| Genentech USA, Inc. | $13,083 |
|---|---|
| Tg Therapeutics, Inc. | $328 |
| UCB, Inc. | $303 |
| EMD Serono, Inc. | $239 |
| Biogen, Inc. | $150 |
| Amgen Inc. | $133 |
| Alexion Pharmaceuticals, Inc. | $108 |
| AbbVie Inc. | $72.00 |
| Compensation for services other than consulting (speaking, faculty) | $12,500 |
|---|---|
| Food and Beverage | $1,534 |
| Travel and Lodging | $440 |
| Consulting Fee | $150 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) Ocrevus; Ocrevus Zunovo · Immunology | $4,760 |
| Genentech USA, Inc. Dec 22, 2025 | Compensation for services other than consulting (speaking, faculty) Ocrevus; Ocrevus Zunovo · Immunology | $4,760 |
| Genentech USA, Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) Ocrevus; Ocrevus Zunovo · Immunology | $2,980 |
| Genentech USA, Inc. Jul 29, 2025 | Travel and Lodging Ocrevus; Ocrevus Zunovo · Immunology · travel to Evansville, IN | $246 |
| Genentech USA, Inc. Dec 22, 2025 | Travel and Lodging Ocrevus; Ocrevus Zunovo · Immunology · travel to Merrillville, IN | $171 |
| Biogen, Inc. May 14, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
| Genentech USA, Inc. May 13, 2025 | Travel and Lodging Ocrevus; Ocrevus Zunovo · Immunology · travel to Fishers, IN | $22.40 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $577,406 in research payments for these studies, mostly to the institutions running them.
- A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company · Recruiting · NCT06566170 - Ocrelizumab RMS High Dose Study
Genentech, Inc. - Evaluation of Fenebrutinib in RMS patients II
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.